Key result
Mexiletine paradoxically worsened QT prolongation in a patient with the SCN5A F1473S mutation by rescuing the trafficking defect of mutant proteins, thereby increasing peak sodium current.
Why the study?
Does mexiletine improve or worsen electrophysiological abnormalities in long-QT syndrome type 3 caused by the SCN5A F1473S mutation?
Case Report (n=1)
Does mexiletine improve or worsen electrophysiological abnormalities in long-QT syndrome type 3 caused by the SCN5A F1473S mutation?
Mexiletine can paradoxically exacerbate QT prolongation in LQT3 patients with specific SCN5A mutations by facilitating the trafficking of mutant proteins.
Answers are grounded in this paper and cite their sources.
Mexiletine warrants caution in LQT3 with trafficking-defective SCN5A mutations; leaves open mutation-specific effects for prospective validation.
RATIONALE: Sodium channel blockers are used as gene-specific treatments in long-QT syndrome type 3, which is caused by mutations in the sodium channel gene (SCN5A). Response to treatment is influenced by biophysical properties of mutations. OBJECTIVE: We sought to investigate the unexpected deleterious effect of mexiletine in a mutation combining gain-of- function and trafficking abnormalities. METHODS AND RESULTS: A long-QT syndrome type 3 child experienced paradoxical QT prolongation and worsening of arrhythmias after mexiletine treatment. The SCN5A mutation F1473S expressed in HEK293 cells presented a right-ward shift of steady-state inactivation, enlarged window current, and huge sustained sodium current. Unexpectedly, it also reduced the peak sodium current by 80%. Immunostaining showed that mutant Nav1.5 is retained in the cytoplasm. Incubation with 10 micromol/L mexiletine rescued the trafficking defect of F1473S, causing a significant increase in peak current, whereas sustained current was unchanged. Using a Markovian model of the Na channel and a model of human ventricular action potential, we showed that simulated exposure of F1473S to mexiletine paradoxically increased action potential duration, mimicking QT prolongation seen in the index patient on mexiletine treatment. CONCLUSIONS: Sodium channel blockers are largely used to shorten QT intervals in carriers of SCN5A mutations. We provided evidence that these agents may facilitate trafficking of mutant proteins, thus exacerbating QT prolongation. These data suggest that caution should be used when recommending this class of drugs to carriers of mutations with undefined electrophysiological properties.
No takes yet. Share an insight, caveat, or question.
Ruan et al. (2010) conducted a case report in Long QT syndrome type 3 (n=1). Mexiletine was evaluated on Electrophysiological properties and QT interval. Mexiletine paradoxically worsened QT prolongation in a patient with the SCN5A F1473S mutation by rescuing the trafficking defect of mutant proteins, thereby increasing peak sodium current.
Synapse has enriched 10 related papers. Consider them for comparative context: